{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:37:26Z","timestamp":1788957446570,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:00:00Z","timestamp":1720915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010586","name":"Helse Bergen HF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.msard.2024.105770","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:16:43Z","timestamp":1721067403000},"page":"105770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients"],"prefix":"10.1016","volume":"89","author":[{"given":"Hilde M.","family":"Torgauten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese Bredholt","family":"Onyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Ljostveit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik I.","family":"Hallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond T.","family":"Serkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Langeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Jane","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105770_bib0001","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105770_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577788","article-title":"Humoral and cellilar immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab","volume":"362","author":"Adamec","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.msard.2024.105770_bib0003","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med."},{"issue":"11","key":"10.1016\/j.msard.2024.105770_bib0004","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.msard.2024.105770_bib0005","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1111\/ene.15492","article-title":"B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients","volume":"29","author":"Asplund H\u00f6gelin","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2024.105770_bib0006","unstructured":"Chi Square Calculator 2x2 (socscistatistics.com) [[Internet].]. [23.11.2023]. Available from: https:\/\/www.socscistatistics.com\/tests\/chisquare\/default2.aspx."},{"key":"10.1016\/j.msard.2024.105770_bib0007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s43856-022-00091-x","article-title":"A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern","volume":"2","author":"Ertesv\u00e5g","year":"2022","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B-cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105770_bib0009","article-title":"Humoral and cellular immunity in convalesecent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies","volume":"59","author":"Habek","year":"2002","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105770_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jmsacl.2022.07.004","article-title":"Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry","volume":"25","author":"Hallin","year":"2022","journal-title":"J. Mass Spectrom. Adv. Clin. Lab."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1352458514561911","article-title":"The Charcot Lecture | beating MS: a story of B cells, with twists and turns","volume":"21","author":"Hauser","year":"2015","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.105770_bib0012","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2024.105770_bib0013","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105770_bib0014","article-title":"B- and T-cell responses after SARS-CoV-2 vaccination in patients with multiple sclerosis receiving disease modifying therapies: immunological patterns and clinical implications","volume":"12","author":"Iannetta","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.105770_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104556","article-title":"Predictors of hospitalization due to infection in rituximab-treated MS patients","volume":"71","author":"Karlowicz","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/jnnp-2021-327612","article-title":"Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations","volume":"94","author":"K\u00f6nig","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.105770_bib0017","article-title":"Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: a case-ascertained study","volume":"3","author":"Kuwelker","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"issue":"6","key":"10.1016\/j.msard.2024.105770_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple sclerosis, disease-modifying therapies, and infections","volume":"10","author":"Langer-Gould","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2024.105770_bib0019","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2024.105770_bib0020","series-title":"WHO's response to COVID-19 - 2021 Annual Report","article-title":"WHO's response to COVID-19 - 2021 annual report","author":"Michael","year":"2022"},{"issue":"3","key":"10.1016\/j.msard.2024.105770_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2024.105770_bib0022","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/jnnp-2021-328197","article-title":"Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab","volume":"93","author":"R\u00e4uber","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2024.105770_bib0023","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/13524585221134216","article-title":"T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy","volume":"29","author":"Reder","year":"2023","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.105770_bib0024","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMa Neurol."},{"issue":"20","key":"10.1016\/j.msard.2024.105770_bib0025","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.msard.2024.105770_bib0026","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1177\/13524585221102918","article-title":"Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies","volume":"28","author":"Schiavetti","year":"2022","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2024.105770_bib0027","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1177\/13524585221094478","article-title":"Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis","volume":"28","author":"Schwarz","year":"2022","journal-title":"Mult. Scler."},{"issue":"19","key":"10.1016\/j.msard.2024.105770_bib0028","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105770_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.msard.2024.105770_bib0030","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51408","article-title":"DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France","volume":"8","author":"Sormani","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.26251","article-title":"COVID-19 vaccine response in people with multiple sclerosis","volume":"91","author":"Tallantyre","year":"2022","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105770_bib0032","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0033","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes. Infect."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0034","article-title":"Torkildsen \u00d8. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2024.105770_bib0035","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41467-021-22045-y","article-title":"A haemagglutination test for rapid detection of antibodies to SARS-CoV-2","volume":"12","author":"Townsend","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.msard.2024.105770_bib0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/infdis\/jiaa737","article-title":"SARS-CoV-2-specific neutralizing antibody responses in norwegian health care workers after the first wave of COVID-19 pandemic: a prospective cohort study","volume":"223","author":"Trieu","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.msard.2024.105770_bib0037","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/13524585231185247","article-title":"Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination","volume":"29","author":"Zaloum","year":"2023","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2024.105770_bib0038","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","article-title":"Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient","volume":"27","author":"Zhou","year":"2020","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400347X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400347X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T19:21:07Z","timestamp":1724008867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400347X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"alternative-id":["S221103482400347X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105770","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105770"}}